<DOC>
	<DOCNO>NCT00549679</DOCNO>
	<brief_summary>This study evaluate safety tolerability cfor first time mild moderate COPD patient .</brief_summary>
	<brief_title>Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>6- ( ( 3- ( ( dimethylamino ) carbonyl ) phenyl ) sulfonyl ) -8-methyl-4- ( ( 3-methyloxyphenyl ) amino ) -3-quinolinecarboxamide</mesh_term>
	<criteria>Male adult female adult nonchildbearing potential 40 75 year age ( inclusive ) . Subjects clinical diagnosis COPD accordance European Respiratory Society Consensus Statement subject categorise moderate COPD define GOLD guideline 2006 [ GOLD , 2006 ] Subjects cigarette smoke history ≥ 10 pack year ( 1 pack year = 20 cigarette smoke per day 1 year equivalent ) . Both current former smoker eligible enrol . A former smoker define subject smoked ≥6 month Visit 1 . Subjects postbronchodilator FEV1 FVC ratio ( FEV1/FVC ) &lt; 0.7 Visit 1 . Subjects assess 30 ( ± 5 ) minute receive salbutamol 400 μg . Subjects postbronchodilator FEV1 ≥ 50 % &lt; 80 % predict normal height , age sex Visit 1 . Subjects assess 30 ( ± 5 ) minute receive salbutamol 400 μg . Subjects normal echocardiogram screening , define absence clinically significant wall motion , chamber size valvular abnormalities The subject must capable give informed consent comply study requirement timetable . Women premenopausal childbearing potential . Subjects weigh less 50 kilogram ( kg ) . Subjects obese define body mass index ( BMI ) &gt; 30 . Subjects current diagnosis asthma . Subjects require hospitalisation treatment oral corticosteroid and/or antibiotic therapy acute worsen COPD low respiratory tract infection 6 week prior Screening . Subjects receive treatment oral , intravenous , topical intraarticular corticosteroid within 6 week Screening thereafter Subjects active tuberculosis , sarcoidosis clinically overt bronchiectasis . Subjects history type malignancy exception successfully treat squamous cell cancer skin . Subjects rheumatoid arthritis , connective tissue disorder condition know associate chronic inflammation ( e.g . Inflammatory Bowel Disease ) . Subjects chronic infection ( last longer 6 month ) gingivitis , periodontitis , prostatitis , gastritis , urinary tract infection . Subjects acute infection , sinus symptom , significant trauma ( burn , fracture ) . Subjects clinically significant renal disease , diabetes mellitus/metabolic syndrome , hypertension clinically significant cardiovascular , neurological , endocrine , haematological abnormality uncontrolled permitted therapy . Subjects participate GSK study/studies involve administration COA . The subject screening ECG parameter outside range specify protocol . Subjects hypoxaemia Risk factor human immunodeficiency virus ( HIV ) , Hepatitis B Hepatitis C infection Screening ( Visit 1 ) . Subjects undergone surgery include lung volume reduction surgery last six month condition prevent perform spirometry . Subjects history ( suspected history ) alcohol misuse recreational substance abuse . Subjects require treatment follow start runin period ( Day 14 ) end treatment phase : Inhaled corticosteroid Inhaled cromolyn sodium nedocromil Xanthines ( theophylline preparation ) . Leukotriene modifier Tiotropium Longacting inhaled beta2agonists ( salmeterol , formoterol ) Oral beta2agonists Subjects unable abstain course medication run phase include nonsteroidal antiinflammatory drug ( NSAIDs ) , antidepressant drug , antihistamine , antirhinitis hay fever medication , short act inhaled betaagonists , ipratropium bromide paracetamol ( 4 g per day ) treatment minor ailment ( eg headache ) 48h first dose followup visit . Subjects require medication dose follow may exclude principal investigator discretion . Subjects know hypersensitivity salbutamol ipratropium bromide . Subjects participate plan participate active phase pulmonary rehabilitation programme study . Subjects receive investigational drug within 30 day within five drug halflives investigational drug ( whichever longer ) . Subjects clinically relevant abnormality detect assessment Screening . Subjects experience exacerbation runin period require treatment oral corticosteroid and/or macrolide antibiotic and/or hospitalisation .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
	<keyword>COPD</keyword>
	<keyword>Repeat Dose</keyword>
	<keyword>GSK256066</keyword>
</DOC>